DIFFUSION MODEL-BASED POSTERIOR DISTRIBUTION PREDICTION FOR KINETIC PARAMETER ESTIMATION IN DYNAMIC PET.

Positron Emission Tomography (PET) is a valuable imaging method for studying molecular-level processes in the body, such as hyperphosphorylated tau (p-tau) protein aggregates, a hallmark of several neurodegenerative diseases including Alzheimer's disease. P-tau density and cerebral perfusion can be quantified from PET data using tracer kinetic modeling techniques. However, noise in PET images leads to uncertainty in the estimated kinetic parameters.

Effects of List-Mode-Based Intraframe Motion Correction in Dynamic Brain PET Imaging.

Motion is unavoidable in dynamic [F]-MK6240 Positron Emission Tomography (PET) imaging, especially in Alzheimer's disease (AD) research requiring long scan duration. To understand how motion correction affects quantitative analysis, we investigated two approaches: II-MC, which corrects for both inter-frame and intra-frame motion, and IO-MC, which only corrects for inter-frame motion. These methods were applied to 83 scans from 34 subjects, and we calculated distribution volume ratios (DVR) using the multilinear reference tissue model with two parameters (MRTM2) in tau-rich brain regions.

PET mapping of receptor occupancy using joint direct parametric reconstruction.

Unlabelled: Receptor occupancy (RO) studies using PET neuroimaging play a critical role in the development of drugs targeting the central nervous system (CNS). The conventional approach to estimate drug receptor occupancy consists in estimation of binding potential changes between two PET scans (baseline and post-drug injection). This estimation is typically performed separately for each scan by first reconstructing dynamic PET scan data before fitting a kinetic model to time activity curves.

Radiosynthesis automation, non-human primate biodistribution and dosimetry of K channel tracer [C]3MeO4AP.

Background: 4-Aminopyridine (4AP) is a medication for the symptomatic treatment of multiple sclerosis. Several 4AP-based PET tracers have been developed for imaging demyelination. In preclinical studies, [C]3MeO4AP has shown promise due to its high brain permeability, high metabolic stability, high plasma availability, and high in vivo binding affinity.

PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator.

Stimulation of the M muscarinic acetylcholine receptor reduces striatal hyperdopaminergia, suggesting its potential as a therapeutic target for schizophrenia. Emraclidine (CVL-231) is a novel, highly selective, positive allosteric modulator (PAM) of M4 muscarinic acetylcholine receptors i.e.